ImmunityBio (IBRX) 주식 개요

생명공학 회사인 이뮤니티바이오는 환자의 면역 체계를 활성화하고 암과 전염병에 대한 지속적인 보호를 제공하도록 설계된 차세대 면역 요법의 혁신, 개발 및 상용화에 주력하고 있습니다. 자세히 보기

IBRX 펀더멘털 분석
스노우플레이크 점수
가치 평가	2/6
미래 성장	5/6
과거 실적	0/6
재무 건전성	1/6
배당	0/6

강점

공정 가치 추정치보다 낮은 78.4% 에서 거래

수익은 매년 67.63% 증가할 것으로 예상됩니다.

위험 분석

cash runway 경력이 1년 미만입니다.

마이너스 주주 지분

지난 1년 동안 주주가 희석되었습니다.

지난 3개월 동안 주가 변동성이 US 시장과 비교해 높았습니다.

IBRX Community Fair Values

Create Narrative

See what 86 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

40.7% undervalued

AnalystConsensusTarget

2mo ago

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

27.3% undervalued

AnalystLowTarget

2mo ago

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Top Analyst Narratives

40.7% undervalued

AnalystConsensusTarget

2mo ago

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

27.3% undervalued

AnalystLowTarget

2mo ago

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

View all narratives

ImmunityBio, Inc. 경쟁사

가격 이력 및 성과

ImmunityBio 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$8.00
52주 최고가	US$12.43
52주 최저가	US$1.95
베타	0.073
1개월 변동	3.90%
3개월 변동	32.89%
1년 변동	185.71%
3년 변동	186.74%
5년 변동	-49.04%
IPO 이후 변동	-79.33%

최근 뉴스 및 업데이트

분석 기사 • May 11

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...

Recent updates

분석 기사 • May 11

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...

Seeking Alpha • Apr 17

Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva

Summary ImmunityBio is transitioning from a single-product biotech to a potential multi-billion-dollar oncology and cell therapy platform company. Anktiva’s commercial momentum is strong, with 1Q26 revenue up 168% YoY and FY25 revenue reaching $113 million, supported by guideline inclusion and global approvals. The Leonardo platform is central to the long-term bull case, aiming to industrialize NK-cell therapies through scalable manufacturing and hospital partnerships. IBRX's valuation is aggressive at 76x trailing sales, leaving little room for regulatory or commercial setbacks; near-term growth hinges on FDA sBLA acceptance for Anktiva label expansion. Read the full article on Seeking Alpha

새로운 내러티브 • Apr 01

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 18

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 04

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?

분석 기사 • Aug 07

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...

Seeking Alpha • Apr 29

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking Alpha

Seeking Alpha • Mar 07

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking Alpha

Seeking Alpha • Jan 17

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking Alpha

Seeking Alpha • Dec 11

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Summary Anktiva received FDA approval in April 2024 for BCG-unresponsive NMIBC. Q3 revenue was $5.954 million, but high R&D and SG&A expenses led to an $80.253 million operational loss, with notable share dilution. Financial health shows a current ratio over 2.0, but high long-term debt and a $34 million monthly cash burn raise concerns. ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. IBRX remains a "sell" due to ongoing dilution, financial risks, and limited upside despite Anktiva's potential in NMIBC. Read the full article on Seeking Alpha

Seeking Alpha • Oct 25

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Summary ImmunityBio's Anktiva shows promise in cancer immunotherapy, with initial sales of $900K and ongoing studies in various cancers, including non-small cell lung cancer. Despite high debt and cash burn, friendly debt terms from entities connected to the founder mitigate financial risks, maintaining shareholder value. The company's novel platforms, like the CD19 t-haNK therapy, diversify its pipeline, reducing reliance on Anktiva alone for future growth. While IBRX has significant upside potential, any negative news could deflate the stock's hype-driven valuation, making it a high-risk investment. Read the full article on Seeking Alpha

Seeking Alpha • Oct 07

ImmunityBio: Moving The Needle

Summary ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding. I plan to capitalize on the current sell-off, placing buy orders around $3.50-$4.00, and setting sell targets at $9 and $12.25 per share. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Summary Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls. Anktiva's competitive position in a diversified NMIBC market is strong, but the financial entanglement with Dr. Soon-Shiong poses significant risks for retail investors. Read the full article on Seeking Alpha

주주 수익률

	IBRX	US Biotechs	US 시장
7D	-1.4%	-3.8%	-0.7%
1Y	185.7%	30.0%	24.4%

수익률 대 산업: IBRX은 지난 1년 동안 30%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: IBRX은 지난 1년 동안 24.4%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is IBRX's price volatile compared to industry and market?
IBRX volatility
IBRX Average Weekly Movement	15.4%
Biotechs Industry Average Movement	11.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.2%

안정적인 주가: IBRX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: IBRX의 주간 변동성(15%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.

회사 소개

설립	직원 수	CEO	웹사이트
n/a	688	Rich Adcock	immunitybio.com

생명공학 회사인 이뮤니티바이오는 환자의 면역 체계를 활성화하고 암과 전염병에 대한 지속적인 보호를 제공하기 위해 고안된 차세대 면역 요법을 혁신, 개발 및 상용화하는 데 주력하고 있습니다. 사이토카인 융합 단백질, DNA 및 백신 벡터, 세포 치료제를 포함한 생물학적 제품 및 제품 후보를 개발하기 위한 플랫폼을 보유하고 있습니다. 이 회사의 플랫폼은 액체 및 고형 종양에 대한 임상 시험에서 연구될 예정인 최초의 인간 대상 치료제를 생성했습니다.

ImmunityBio, Inc. 기초 지표 요약

ImmunityBio의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
IBRX 기초 통계
시가총액	US$8.35b
순이익 (TTM)	-US$854.53m
매출 (TTM)	US$140.98m

59.4x

주가매출비율(P/S)

-9.8x

주가수익비율(P/E)

IBRX는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
IBRX 손익계산서 (TTM)
매출	US$140.98m
매출원가	US$933.00k
총이익	US$140.04m
기타 비용	US$994.58m
순이익	-US$854.53m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)	-0.82
총이익률	99.34%
순이익률	-606.15%
부채/자본 비율	-124.7%

IBRX의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/18 10:42
종가	2026/05/18 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ImmunityBio, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Jason Kolbert	D. Boral Capital LLC.

ImmunityBio (IBRX) 주식 개요

강점

위험 분석

Analyst Price Targets

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Top Analyst Narratives

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

ImmunityBio, Inc. 경쟁사

Madrigal Pharmaceuticals

Krystal Biotech

Xenon Pharmaceuticals

Syndax Pharmaceuticals

가격 이력 및 성과

최근 뉴스 및 업데이트

ImmunityBio Stock Sinks 21% After FDA Warning Spurs Class Action Lawsuits

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

New major risk - Financial position

Forecast to breakeven in 2028

First quarter 2026 earnings released: US$0.62 loss per share (vs US$0.15 loss in 1Q 2025)

ImmunityBio, Inc., Annual General Meeting, Jun 09, 2026

Recent updates

ImmunityBio Stock Sinks 21% After FDA Warning Spurs Class Action Lawsuits

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

New major risk - Financial position

Forecast to breakeven in 2028

First quarter 2026 earnings released: US$0.62 loss per share (vs US$0.15 loss in 1Q 2025)

ImmunityBio, Inc., Annual General Meeting, Jun 09, 2026

ImmunityBio Announces Anktiva Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients

Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva

ImmunityBio Inc Addresses FDA Correspondence and Implements Enhanced Advertising Compliance Measures

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone

ImmunityBio, Inc. Announces Approval For ANKTIVA In Macau Sar China For Bcg-Unresponsive Nmibc With Cis ± Papillary Tumors

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Forecast breakeven date moved forward to 2027

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

ImmunityBio, Inc. Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA®? Plus BCG Versus BCG Alone in BCG-Naive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

President exercised options and sold US$675k worth of stock

New major risk - Financial position

Full year 2025 earnings: EPS exceeds analyst expectations

ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio, Inc. Reports Productive Regulatory Engagement with Saudi Food and Drug Authority At USA -Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

President exercised options and sold US$971k worth of stock

ImmunityBio, Inc. Launches Phase 2 Chemotherapy-FreeCAR-NK Cell Therapy Trial with Anktiva (ResQ215B) in Indolent Lymphomas

ImmunityBio, Inc. Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy

Price target increased by 9.6% to US$11.40

Board Member notifies of intention to sell stock

Immunitybio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

Consensus estimates of losses per share improve by 10%

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

New minor risk - Share price stability

Saudi Fda Grants Accelerated Approval to ImmunityBio , Inc.'s Anktiva for Non-Muscle Invasive Bladder Cancer Witharcinoma In-Situ

ImmunityBio, Inc. Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Forecast to breakeven in 2028

ImmiBio, Inc. Announces Treatment with ANKTIVA®? (nogapendekin Alfa Inbakicept-pmln) Plus Bacillus Calmette-Guerin

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for Anktiva with Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

New minor risk - Financial position

Third quarter 2025 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

ImmunityBio, Inc. Announces its ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. Announces Initial Data Shows 100% Disease Control in 5 Out of 5 Patients with Recurrent Glioblastoma with Two Patients in Near Complete Response Treated with Immunotherapy's ANKTIVA®?, NK Cell Therapy Plus Optune Gio®? Device

ImmunityBio, Inc. Announces Phase 2 Study of ANKTIVA®? in Patients with Long COVID

Price target decreased by 16% to US$10.20

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free

ImmunityBio, Inc. Announces Houston's Michael E. DeBakey Department of Veterans Affairs Medical Center Is Among the First VA Hospitals to Helpister ANKTIVA to Bladder Cancer Patients

No longer forecast to breakeven

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield™ Platform, in Patients with Solid Tumors

First quarter 2025 earnings: EPS misses analyst expectations